Literature DB >> 28230006

Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma.

Ping Li1, Tang Xiao-Yin1, Dan Cui1, Jia-Chang Chi1, Zhi Wang1, Tao Wang1, Xing-Xing Qi1, Bo Zhai1.   

Abstract

BACKGROUND: This study was conducted to evaluate the safety and efficacy of ultrasound (US)-guided percutaneous radiofrequency ablation (RFA) for multiple breast fibroadenoma as an alternative to surgical resection. PATIENTS AND METHODS: Sixty-five patients with multiple breast fibroadenoma accepted general anesthesia and US-guided percutaneous RFA in our hospital from September 2014 to January 2016. Contrast-enhanced US (CEUS) was used immediately after operation to determine whether the tumor was ablated completely. The complete ablation rate (CAR) and the change of focal volume were evaluated by CEUS at the 1st month and the 3rd month after operation.
RESULTS: All the patients were diagnosed by needle biopsy. Among all the patients, 256 nodules were found. Forty-six nodules (17.96%) were located <5 mm from epidermis; 26 nodules (10.15%) were located below areola. Complete ablation was achieved for 251 nodules (98.04%) after the 1st month of operation. The volume reduce rate was 39.06% and 75.99% at the 1st and the 3rd month after operation, respectively, of which 45 nodules were completely absorbed (17.58%). There was a statistically significant difference of the volume reduction rate (VRR) after operation (P < 0.01) compared with preoperative breast nodules volume. There were no complications such as skin burn, hemorrhage, and hematoma, nipple discharge in the process during and after RFA.
CONCLUSION: Given advantages of high CAR, mild injury, rapid recovery, and cosmetic outcome desired by the patients, RFA has the potential to become the preferred method in the treatment of breast fibroadenoma.

Entities:  

Mesh:

Year:  2016        PMID: 28230006     DOI: 10.4103/jcrt.JCRT_966_16

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  4 in total

1.  Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial.

Authors:  Sadaf Alipour; Mahboubeh Abedi; Azin Saberi; Arezoo Maleki-Hajiagha; Firoozeh Faiz; Saeed Shahsavari; Bita Eslami
Journal:  BMC Endocr Disord       Date:  2021-08-20       Impact factor: 2.763

2.  Evaluation of Ultrasound-Guided Radiofrequency Ablation as a Treatment Option for Papillary Thyroid Microcarcinoma in the Isthmus: A Retrospective Study.

Authors:  Qing Song; Hanjing Gao; Xiaoqi Tian; Ling Ren; Yu Lan; Lin Yan; Yukun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-09       Impact factor: 5.555

3.  Effects of oral N-acetyl cysteine on pain and plasma biochemical parameters in fibrocystic breast disorder: A randomized controlled trial.

Authors:  Esmail Abdorrahim Kashi; Ali Akbar Salmani; Shima Shafagh; Gholam Abbas Mousavi; Noushin Mousavi; Mahmoud Heydari; Abbas Hajian
Journal:  Surg Open Sci       Date:  2022-07-02

4.  Ultrasound radiomics features predicting the dosimetry for focused ultrasound surgery of benign breast tumor: A retrospective study.

Authors:  Mengdi Liang; Cai Zhang; Tiansong Xia; Rui Chen; Xinyang Wang; Miaomiao Weng; Hui Xie; Lin Chen; Xiaoan Liu; Shui Wang
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.